Concurrent treatment with gonadotropin-releasing hormone agonists for chemotherapy-induced ovarian damage in premenopausal women with breast cancer: A meta-analysis of randomized controlled trials

Breast

Volumn 22, Issue 2, 2013, Pages 150-157

  Yang, Bo ^a   Shi, Weiwei ^a   Yang, Junlan ^a   Liu, Hui ^a   Zhao, Hong ^a   Li, Xiaoyan ^b   Jiao, Shunchang ^a  

^a CHINESE PLA GENERAL HOSPITAL   (China)

^b BEIJING INSTITUTE OF MICROBIOLOGY AND EPIDEMIOLOGY   (China)

Author keywords

Breast cancer; Chemotherapy; GnRH agonists; Meta analysis; Ovarian damage

Indexed keywords

ANTHRACYCLINE; CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUOROURACIL; GONADORELIN AGONIST; GOSERELIN; METHOTREXATE; TAXANE DERIVATIVE; TRIPTORELIN;

ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CHEMOTHERAPY INDUCED OVARIAN DAMAGE; DRUG INDUCED DISEASE; DRUG INDUCED HEADACHE; FOLLOW UP; HOT FLUSH; HUMAN; INSOMNIA; MENSTRUATION; META ANALYSIS; MOOD SWING; MULTIPLE CYCLE TREATMENT; OVARY DISEASE; PARTHENOGENESIS; PREGNANCY RATE; PREMATURE OVARIAN FAILURE; PREMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT; SIDE EFFECT; SWEATING; UROGENITAL TRACT DISEASE;

EID: 84875486602     PISSN: 09609776     EISSN: 15323080     Source Type: Journal    
DOI: 10.1016/j.breast.2012.12.008     Document Type: Article

References (34)

1. Jemal A., Siegel R., Xu J., Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010, 60:277-300.
2. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005, 365:1687-1717. Early Breast Cancer Trialists' Collaborative Group.
3. Clarke M., Coates A.S., Darby S.C., Davies C., Gelber R.D., Godwin J., et al. Adjuvant chemotherapy in oestrogen-receptor-poor breast cancer: patient-level meta-analysis of randomised trials. Lancet 2008, 371:29-40.
4. Tsutsui K., Bentley G.E., Bedecarrats G., Osugi T., Ubuka T., Kriegsfeld L.J. Gonadotropin-inhibitory hormone (GnIH) and its control of central and peripheral reproductive function. Front Neuroendocrinol 2010, 31:284-295.
5. Recchia F., Sica G., De Filippis S., Saggio G., Rosselli M., Rea S. Goserelin as ovarian protection in the adjuvant treatment of premenopausal breast cancer: a phase II pilot study. Anticancer Drugs 2002, 13:417-424.
6. Gilani M.M., Hasanzadeh M., Ghaemmaghami F., Ramazanzadeh F. Ovarian preservation with gonadotropin-releasing hormone analog during chemotherapy. Asia-Pac J Clin Oncol 2007, 3:79-83.
7. Recchia F., Saggio G., Amiconi G., Di Blasio A., Cesta A., Candeloro G., et al. Gonadotropin-releasing hormone analogues added to adjuvant chemotherapy protect ovarian function and improve clinical outcomes in young women with early breast carcinoma. Cancer 2006, 106:514-523.
8. Del Mastro L., Catzeddu T., Boni L., Bell C., Sertoli M.R., Bighin C., et al. Prevention of chemotherapy-induced menopause by temporary ovarian suppression with goserelin in young, early breast cancer patients. Ann Oncol 2006, 17:74-78.
9. Urruticoechea A., Arnedos M., Walsh G., Dowsett M., Smith I.E. Ovarian protection with goserelin during adjuvant chemotherapy for pre-menopausal women with early breast cancer (EBC). Breast Cancer Res Treat 2008, 110:411-416.
10. Badawy A., Elnashar A., El-Ashry M., Shahat M. Gonadotropin-releasing hormone agonists for prevention of chemotherapy-induced ovarian damage: prospective randomized study. Fertil Steril 2009, 91:694-697.
11. Sverrisdottir A., Nystedt M., Johansson H., Fornander T. Adjuvant goserelin and ovarian preservation in chemotherapy treated patients with early breast cancer: results from a randomized trial. Breast Cancer Res Treat 2009, 117:561-567.
12. Gerber B., von Minckwitz G., Stehle H., Reimer T., Felberbaum R., Maass N., et al. Effect of luteinizing hormone-releasing hormone agonist on ovarian function after modern adjuvant breast cancer chemotherapy: the GBG 37 ZORO study. J Clin Oncol 2011, 29:2334-2341.
13. Del Mastro L., Boni L., Michelotti A., Gamucci T., Olmeo N., Gori S., et al. Effect of the gonadotropin-releasing hormone analogue triptorelin on the occurrence of chemotherapy-induced early menopause in premenopausal women with breast cancer: a randomized trial. J Am Med Assoc 2011, 306:269-276.
14. Munster P.N., Moore A.P., Ismail-Khan R., Cox C.E., Lacevic M., Gross-King M., et al. Randomized trial using gonadotropin-releasing hormone agonist triptorelin for the preservation of ovarian function during (neo)adjuvant chemotherapy for breast cancer. J Clin Oncol 2012, 30:533-538.
15. Clowse M.E., Behera M.A., Anders C.K., Copland S., Coffman C.J., Leppert P.C., et al. Ovarian preservation by GnRH agonists during chemotherapy: a meta-analysis. J Womens Health (Larchmt) 2009, 18:311-319.
16. Chen H., Li J., Cui T., Hu L. Adjuvant gonadotropin-releasing hormone analogues for the prevention of chemotherapy induced premature ovarian failure in premenopausal women. Cochrane Database Syst Rev 2011, CD008018.
17. Bedaiwy M.A., Abou-Setta A.M., Desai N., Hurd W., Starks D., El-Nashar S.A., et al. Gonadotropin-releasing hormone analog cotreatment for preservation of ovarian function during gonadotoxic chemotherapy: a systematic review and meta-analysis. Fertil Steril 2011, 95:906.e1-4-914.e1-4.
18. Higgins J.P., Green S. Cochrane handbook for systematic reviews of interventions version 5.0.2 2009, The Cochrane Collaboration.
19. Higgins J.P., Thompson S.G., Deeks J.J., Altman D.G. Measuring inconsistency in meta-analyses. BMJ 2003, 327:557-560.
20. Begg C.B., Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics 1994, 50:1088-1101.
21. Egger M., Davey Smith G., Schneider M., Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997, 315:629-634.
22. Conway G.S. Premature ovarian failure. Br Med Bull 2000, 56:643-649.
23. Rebar R.W. Premature ovarian failure. Obstet Gynecol 2009, 113:1355-1363.
24. Christin-Maitre S., Braham R. General mechanisms of premature ovarian failure and clinical check-up. Gynecol Obstet Fertil 2008, 36:857-861.
25. Beranger R., Hoffmann P., Christin-Maitre S., Bonneterre V. Occupational exposures to chemicals as a possible etiology in premature ovarian failure: a critical analysis of the literature. Reprod Toxicol 2012, 33:269-279.
26. Bines J., Oleske D.M., Cobleigh M.A. Ovarian function in premenopausal women treated with adjuvant chemotherapy for breast cancer. J Clin Oncol 1996, 14:1718-1729.
27. Tham Y.L., Sexton K., Weiss H., Elledge R., Friedman L.C., Kramer R. The rates of chemotherapy-induced amenorrhea in patients treated with adjuvant doxorubicin and cyclophosphamide followed by a taxane. Am J Clin Oncol 2007, 30:126-132.
28. Bukman A., Heineman M.J. Ovarian reserve testing and the use of prognostic models in patients with subfertility. Hum Reprod Update 2001, 7:581-590.
29. Anderson R.A., Themmen A.P., Al-Qahtani A., Groome N.P., Cameron D.A. The effects of chemotherapy and long-term gonadotrophin suppression on the ovarian reserve in premenopausal women with breast cancer. Hum Reprod 2006, 21:2583-2592.
30. Lee S.J., Schover L.R., Partridge A.H., Patrizio P., Wallace W.H., Hagerty K., et al. American Society of Clinical Oncology recommendations on fertility preservation in cancer patients. J Clin Oncol 2006, 24:2917-2931.
31. Moore H.C. Fertility and the impact of systemic therapy on hormonal status following treatment for breast cancer. Curr Oncol Rep 2000, 2:587-593.
32. Minton S.E., Munster P.N. Chemotherapy-induced amenorrhea and fertility in women undergoing adjuvant treatment for breast cancer. Cancer Control 2002, 9:466-472.
33. Pritchard K.I., Paterson A.H., Paul N.A., Zee B., Fine S., Pater J. Increased thromboembolic complications with concurrent tamoxifen and chemotherapy in a randomized trial of adjuvant therapy for women with breast cancer. National Cancer Institute of Canada Clinical Trials Group Breast Cancer Site Group. J Clin Oncol 1996, 14:2731-2737.
34. Cuzick J., Ambroisine L., Davidson N., Jakesz R., Kaufmann M., Regan M., et al. Use of luteinising-hormone-releasing hormone agonists as adjuvant treatment in premenopausal patients with hormone-receptor-positive breast cancer: a meta-analysis of individual patient data from randomised adjuvant trials. Lancet 2007, 369:1711-1723.